Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

ASCO GU 2017: Discussion program on prostate and bladder cancer

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida.

An international multidisciplinary panel discussed a selection of topics and new data on prostate and bladder cancer. During a live connection, questions were submitted by participants of the ASCO Direct GU Virtual meetings in 7 different countries (Austria, Belgium, Brazil, Germany, Netherlands, United Arabic Emirates and Switzerland)


  • Active surveillance in localized prostate cancer
  • Impact of ProtecT trial results
  • Value of imaging, genomics, and genetics for active surveillance
  • High-risk prostate cancer, definition and therapeutic controversies
  • Value of chemoradiation for bladder cancer
  • Molecular predictors and response to neoadjuvant chemotherapy in bladder cancer


  • Prof. Bertrand Tombal MD PhD, urologist, Université catholique de Louvain, Cliniques universitaires Saint-Luc, Brussels, Belgium
  • Prof. Robert Bristow MD PhD, radiation oncologist, Princess Margaret Hospital, Toronto, Canada
  • Prof. Thomas Bauernhofer MD, medical oncologist, University Clinic for Internal Medicine Karl-Franzens University, Graz, Austria
  • Neil Shore MD, urologist, Atlantic Urology Clinic, Myrtle Beach, USA


  • Catherine Hood PhD


  • Sponsors

    This program is editorially independent and is financially supported by:

Related items